Hepatocellular carcinoma (HCC) ranks third in overall global cancer-related mortality ([@bib32]) accounting for 85--90% of all tumours emerging from the liver in high-incidence areas and between 70 and 75% of cases in lower incidence regions. In a 2008 survey, overseen by the World Health Organisation (WHO), it was reported that there were ∼748 000 new cases of liver cancer diagnosed worldwide, in that year alone, with an estimated 695 000 reported deaths in the same period ([@bib32]). These figures reflect the high mortality rate of this disease owing to multiple contributing factors; most important of which include the absence of monitoring in high-risk populations, insufficient diagnostic resources, and very limited treatment options, many of which require early tumour identification for any potential of curative intervention. As a consequence, the HCC biomarker discovery field is rapidly expanding with new and ongoing research continuing to propose a fast growing list of biomarker candidates. Many of these candidate biomarkers await further validation before being used in conjunction with, or in place of ultrasound scanning as the primary non-invasive test for HCC determination.

The main risk and causative factors for HCC are well described in the literature with a distinct geographical separation observed between established infectious agents such as the hepatitis B and C viruses (HBV and HCV) *vs* an increasing number of lifestyle-related risk factors such as chronic alcohol abuse ([@bib65]) non-alcoholic steatohepatitis, diabetes and obesity ([@bib77]; [@bib29]). The focus of this review is to summarise and explore the new potential candidate biomarkers arising from the surge of proteomic and metabolic profiling studies infiltrating the literature. The advance of these markers through the implementation of systems biology approaches will bring to the forefront robust candidates for enhanced diagnostics and therapies for chronic liver diseases (CLDs; [@bib9]; [@bib58]). The key selection criteria for an ideal biomarker for any disease are for the: Target molecule to be measurable in a non-invasive sample source such as blood or urine.Marker to have excellent diagnostic and/or prognostic abilities for condition of interest (i.e., high sensitivity and specificity).Marker should be amenable to measurement techniques that are reliable, robust, and reproducible and, for use in field analysis should ideally take a simple kit-based format not requiring additional equipment for interpretation.Assay should be cheap and thus accessible to all the populations requiring it.The biomarker should be validated across a broad range of populations.

Currently the most widely used biomarker for HCC, particularly in the developing world where disease burden is greatest is alpha-fetoprotein (AFP). Alpha-fetoprotein ticks several of the boxes in relation to the points mentioned above but fails dramatically in its diagnostic performance and ability, thus significantly reducing its reliability in clinical settings.

The role of AFP in diagnosing HCC and monitoring those at high risk of its development is heavily constrained, with revised guidelines reflecting its significant limitations in this regard. A publication by the American Association for the Study of Liver Diseases (AASLD) summarises that AFP 'lacks adequate sensitivity and specificity for effective surveillance and for diagnosis\' of HCC ([@bib16]). Similarly, the European Association for the Study of the Liver (EASL) does not recommend AFP within the panel of tests for HCC diagnosis ([@bib30]). Not much has been reported on the independent diagnostic ability of AFP, but it is approximated at 0.70, with at least one publication showing area under the curve (AUC) values as low as \<0.60 when used at a cut-off of 100 ng ml^−1^ ([@bib38]). To circumvent this problem, advanced radiological methods are increasingly being relied on as the best non-invasive tools for accurate diagnosis and monitoring of CLD patients. However, as CLDs and their sequelae of conditions inflict their biggest burden in the developing world, this shift has meant that many of the patients mostly in need of monitoring and diagnosis are left to rely on the poor performance of AFP. The AASLD and EASL both recommend routine surveillance of patients with chronic hepatitis infections and fibrosis, to detect HCC at the early disease stage, when curative treatment options such as tumour resection ([@bib16]), ablation ([@bib55]), transarterial chemoembolisation ([@bib56]), and liver transplant, recommended for patients with localised tumours on a background of advanced cirrhosis are still prospective. To make this a reality, there is an urgent need for the identification and conversion into clinical use of affordable, non-invasive, and high-performance diagnostic tools deployable in both the developing and developed worlds.

With the availability of novel state-of-the-art technologies and approaches, medical researchers have in recent years used the tools of mass spectrometry (MS) and proton nuclear magnetic resonance (^1^H NMR) spectroscopy to delve deeper into the human proteome and metabolome from accessible body fluids in order to identify high-performance screening and diagnostic markers capable of detecting and or predicting HCC development. However, there are currently no clinically approved alternatives to AFP that could form robust, non-invasive routine tests available to confidently detect HCC or its main precursor condition of liver cirrhosis (LC) at their early stages. This review aims to summarise and assess literature reports of the application of ^1^H NMR spectroscopy and MS methods to identify and validate the differential expression of proteins, and metabolites potentially exploitable as biomarkers of HCC. Some degree of focus will be given to markers of earlier stages of CLD such as liver fibrosis and LC where they have been reported. However, due to the high degree of variability in research approaches used to validate the expression trends of putative biomarkers and the small sample sizes generally utilised in profiling, a true meta-analysis of all published work is as yet not possible. Part of the selection criteria for inclusion of papers in this review was that all initial discovery of proposed markers was to be conducted using spectroscopic methodologies, it may thus be striking that some of the more widely proposed markers associated with HCC and CLDs are absent. These have mainly been proposed in experiments utilising more classical protein and metabolite identification and measurement methods, and thus do not form the focus of this work. Many of these classical markers have been widely discussed and reviewed in the context of liver diseases ([@bib7]; [@bib61]). Several worthy of mention include des-carboxy prothrombin, squamous cell carcinoma antigen--immunoglobulin M complexes, and chromogranin A, which have been proposed and/or compared with AFP in key publications ([@bib8], [@bib10]; [@bib12]). As the list of candidate markers being identified and proposed byspectroscopic methods increases, it is important that reports are comprehensively amalgamated in order to allow researchers to focus more on validating their robustness and expression patterns using independent methods and platforms. This review is an attempt to accelerate this agenda and to ascertain which panel of metabolites and proteins would offer a parsimonious and robust solution for an effective diagnosis.

Materials and Methods
=====================

This review focuses on biomarkers proposed from sources searched in the databases PubMed and Google Scholar. The exact search procedure is outlined in [Figure 1](#fig1){ref-type="fig"}. For the identification of proteomic papers, the PubMed database was searched with the term '(((Hepatocellular Carcinoma) AND Biomarker) AND Proteomics)\'. For the metabonomics part, a similar PubMed search was conducted (but with the word 'metabonomics\' instead of 'proteomics\'). All returned publications shortlisted for adherence to the inclusion/exclusion criteria stated below were considered for analyses. Since only 10 metabonomic publications were identified on PubMed, an additional Google Scholar search was conducted, which identified a further eight publications. Additional publications were identified by screening all references associated with these primary papers.

The criteria for inclusion in this review were: HCC biomarker studies using plasma, serum, or (for metabonomic papers) urine.HCCs linked to established viral and dietary risk factors with no reports of metastases.Initial discovery conducted on a MS or ^1^H NMR spectroscopy-based platform.

Exclusion criteria were non-English literature reports, studies on tissues, cell lines, or animals. Studies including subjects who underwent surgery or transplant were also excluded in order to avoid cases of recurrent HCC following treatment or intervention -- these recurrences may have unique developmental profiles that could influence scope of targets identified. Once this initial filtering was applied, a secondary criterion including biomarker candidates with multiple reports, that is, the biomarker should have been reported by at least two independent methods or research groups, was applied.

HCC markers proposed by metabonomic studies
-------------------------------------------

The liver is the metabolic hub of humans as most compounds absorbed by the intestine pass through it at least once. Owing to this, it is able to regulate the expression levels of numerous metabolites, which makes metabolomic analyses approaches particularly relevant for the investigation of liver diseases, such as LC and HCC. In recent years, a lot of effort has been put into metabonomic research on CLDs mainly using urine, blood, or hepatic tissue sections. A number of differential metabolites have been reported by the few studies on HCC tumour tissues, suggesting that there are major metabolic changes taking place during disease development and progression. A common finding of these studies is a glycolytic HCC phenotype ([@bib98]; [@bib11]), indicating that the Warburg effect may take place in liver cancer. Although this and other findings give important insight into HCC tumour biology from a clinical perspective, a more important question is whether there exist specific metabolites detectable in biofluids, such as blood or urine, which can serve as biomarkers for the diagnosis of early HCC.

Up to the submission of this review, 22 metabonomic studies matched the inclusion criteria described above and investigated the blood and/or urine metabolome in the context of HCC ([Table 1](#tbl1){ref-type="table"}). Most of these studies are MS based and investigate HCC in the context of HBV or HCV ([Table 2](#tbl2){ref-type="table"}), which reflects the global trend of primary HCC risk factors ([@bib15]). In contrast, the patient cohorts\' ethnicities in these studies did not reflect the geographical distribution of HCC incidence. Although the majority of studies were performed in China, where HCC is a major health issue, only a single study investigated the metabolome of HCC in a sub-Saharan African cohort ([Table 2](#tbl2){ref-type="table"}), where HCC is an equally important health burden ([@bib32]).

Most studies inferred differential expression of metabolites by comparing either serum or urine profiles of HCC patients with control groups, mainly made up of healthy volunteers or cirrhotics. This was accomplished with univariate and/or multivariate statistical methods. Multivariate methods used in these publications not only include partial least squares discriminant analysis (PLS-DA), but also support vector machine and random forest approaches. On average 18 biomarker candidates were identified per study, with only 32% of these using established diagnostic models for comprehensive assessment of diagnostic performance. This low assessment rate makes a meta-analysis impossible at this stage.

The following section is structured according to compound classes to provide an overview of the metabolites that were reported in more than one study. In addition, the diagnostic models that have been reported to perform extremely well in diagnosing HCC will be mentioned at the end of this section.

Bile acids
----------

Bile acids constitute one of the most frequently reported compound classes suggested as discriminating between HCC patients and a control group, be it healthy or CLD. An increase in conjugated bile acids has long been recognised in patients with hepatobiliary diseases in general, such as viral hepatitis, cirrhosis, HCC, and cholangiocarcinoma ([@bib71]). Many metabonomic publications reviewed here confirm an increase in particular conjugated serum bile acids in HCC patients when compared to healthy individuals ([Table 3](#tbl3){ref-type="table"}).

Interestingly, higher bile acid serum levels (glycochenodeoxycholic acid, glycocholic acid, CA, and deoxycholic acid (DCA)) have been found in HCC patients with cirrhosis, than without ([@bib23]), which may indicate that the bile acid concentration is primarily associated with cirrhosis or overall hepatic performance. Evidence for this is given by [@bib24], who found serum bile acids increased in patients with hepatic decompensation, when compared to compensated patients. A closer look at the HCC cohorts\' characteristics of the matched studies reveals that only a few assessed and included the extent of liver disease in the background of HCC or the hepatic compensation/decompensation status in their analyses ([Table 2](#tbl2){ref-type="table"}). This may have significantly biased the results. Other confounding factors that have not been controlled for many studies include (1) the prandial state of the patients (elevated serum levels of certain bile acids have been reported previously in patients after food intake ([@bib50]; [@bib76])) and (2) the size of the tumour mass. Large tumour masses may compromise the ability of non-tumourous liver tissue to produce bile acids, thereby lowering the serum bile acid levels. Although some studies report the fraction of HCC patients in different tumour stages, the majority of studies did not include that information in their data analyses.

Altogether, the level of serum bile acids reported here seems to be associated primarily with cirrhosis and not HCC and we do not recommend this compound group as biomarkers for early HCC without further directed analysis of the bile acids across different stages of cirrhosis. From a mechanistically viewpoint, bile acids may play a role in the development of HCC, for example, by the production reactive oxygen species, thereby producing oxidative stress and DNA damage ([@bib5]). Some of the bile acids have also been described as versatile signalling molecules ([@bib89], [@bib88]; [@bib35]), for instance, lithocholic acid and DCA are both involved in the promotion of energy expenditure and participation in glucidic metabolism by acting on the G-protein-coupled receptor TRG5 ([@bib5]).

Conflicting urinary concentrations of free glycine and taurine, two bile acid conjugates, have also been reported. These equivocal reports may also be explained by the recruitment of heterogeneous study cohorts (which differ in the degree of background liver disease or tumour masses). Since, both of the amino acids, glycine and taurine exhibit a wide range of metabolic activity, it is likely that their serum and urine concentrations in HCC patients reflect multiple metabolic processes, which further complicates the interpretation of these results. Less frequently reported bile compounds include various other bile acid species.

Lysophosphatidylcholines
------------------------

When compared to a healthy control group, nine lysophosphatidylcholines (LPCs) have been reported to be significantly decreased in the sera of HCC patients in multiple publications ([Table 4](#tbl4){ref-type="table"}). The most frequently reported species include LPC C16 : 0, LPC C18 : 0, and LPC C18 : 2. Two of these (LPC 16 : 0 and LPC 18 : 0) have also been reported to be differentially expressed in the sera of HCC patients when compared with cirrhotic patients, with increased serum levels of LPC C18 : 0 and inconclusive findings for LPC C16 : 0. The depletion of LPC C16 : 0 in HCC tumours has recently been described by two independent tissue metabonomic studies ([@bib11]; [@bib44]). Transcriptomic analyses confirmed the overexpression of lysophosphatidylcholine acyltransferase 1 (LPCAT1), which converts LPC C16 : 0 to phosphatidylcholine 18 : 1 ([@bib66]). This upregulation of LPCAT1 could account for the depletion of LPC C16 : 0. However, some LPC species, including 16 : 0, LPC 18 : 0, LPC 20 : 4, and LPC 20 : 5 have also been described as differentially expressed between hepatic decompensated and compensated patients ([@bib24]). As mentioned before, many studies did not control for the background liver disease, that is, hepatic performance, which could have biased the described findings.

LPCs, together with arachidonic acid, may play important roles in the progression of HCC, as they have been described as important players in endothelial cell migration, that is, vascularisation processes ([@bib54]). This finding matches with the observation that hypervascularisation is a frequent feature of HCC. A positive relationship has been described between LPC concentrations and both body weight and inflammatory processes in malignant diseases ([@bib87]). The detection of urinary LPCs in the context of HCC has not been reported.

Free fatty acids
----------------

Although numerous free fatty acid (FFA) species have been described as being discriminatory in serum between HCC patients and a control group, there was no common trend in serum FFA levels observable with some studies reporting increased levels and others reporting a decrease in FFA concentrations ([Table 5](#tbl5){ref-type="table"}). FFA species reported frequently include FFA C16 : 0, FFA C18 : 0, FFA C20 : 4, and FFA C24 : 1. The conflicting reports on the serum concentrations may be a result of heterogenic patient groups, in terms of different diets, gender, comorbidities (such as cardiovascular diseases), and of course the extent of liver damage, that is the hepatic compensation/decompensation status. As was the case for bile acids and LPCs, FFA levels seem to be also influenced by background liver disease ([@bib24]). The association of FFA 16 : 0 and FFA 18 : 0 with hepatitis B and cirrhosis has been described by [@bib23], who investigated HCC patients with and without LC and hepatitis separately. In contrast, increased concentrations of FFA C16 : 0 and FFA C18 : 0 have been confirmed by a tissue metabonomic study on HCC ([@bib44]), indicating that there may be quantitative differences between serum FFA concentrations of HCC and cirrhosis patients.

Other serum lipid compounds found to be discriminative between HCC and healthy controls are FFA C24 : 1 and oleamide. Although FFA 24 : 1 has not been found to discriminate between cirrhosis and HCC patients, oleamide has. Oleamide, the amide of FFA C18 : 1 (oleic acid), exhibits a variety of neuropharmacological effects, including increased food intake ([@bib60]) and relaxation of blood vessels ([@bib41]). Since Oleamide has not been associated with CLDs, nor previously been reported in cancer literature, it may represent a specific marker for HCC. However, further validation studies are required.

Carnitine and related acylesters
--------------------------------

A compound class closely associated to fatty acids and their catabolism, is carnitine and its acylesters. Carnitine is mainly derived from dietary sources and its main function is to transport activated long-chain fatty acids from the cytosol into the mitochondria for energy production via beta-oxidation. Physiologically, almost all free carnitine is intracellular ([@bib18]) and the renal absorption rate is high ([@bib6]). Interestingly, two urinary NMR studies report a trend towards increased urinary levels of free carnitine HCC patients, when compared with a healthy control or cirrhosis group ([Table 6](#tbl6){ref-type="table"}). Since renal function was not assessed in any of the studies considered in this review, and renal diseases, such as the hepatorenal syndrome, are common secondary to cirrhosis and HCC, increased urinary-free carnitine may indicate kidney dysfunction, instead of being specific for HCC. Increased urinary acylcarnitines (esterified acyl groups with carnitine) have been reported in specific FFA oxidation disturbances and after extensive workout ([@bib33]). Urinary acetylcarnitine, however, has not been associated with HCC before and may therefore be a specific HCC biomarker candidate.

The differential serum levels of carnitines, when HCC is compared to a healthy control cohort, seem to exhibit a specific pattern, with mostly increased free carnitine levels, decreased short to medium-chain acylcarnitines and increased levels of long-chain acylcarnitine C18 : 1 and C18 : 2. A major role of short- and medium-chain acylcarnitines is to remove organic acids from organelles such as mitochondria, and eventual excretion in urine and bile. The decrease in serum, however, indicates either an increased excretion rate or a decreased accumulation rate. In contrast, long-chain acylcarnitines are formed intracellularly for the purpose of energy production. Therefore, elevated long-chain acylcarnitine levels could possibly permit an increased FFA transport into mitochondria and hence increase energy production.

The interpretation of these findings should be taken with caution, since carnitine levels can be influenced by many other factors, such as by diet, renal dysfunction or altered biosynthesis rates. Blood acylcarnitines levels may also be influenced by the hepatic fatty acid metabolism, that is, increased (or decreased) acylcarnitine levels due to the increased (or decreased) production of acyl groups in the liver or other tissues.

There is a body of evidence that patients with different cirrhosis aetiologies show specific carnitine profiles. For instance, when compared to healthy volunteers, patients with viral hepatitis-induced cirrhosis (HBV and HCV) showed an increase in plasma long-chain acylcarnitines, whereas patients with alcohol-induced cirrhosis had elevated levels of both, long- and short-chain acylcarnitines ([@bib49]). Clinical studies on [L]{.smallcaps}-carnitine and acetyl-[L]{.smallcaps}-carnitine as a dietary supplement found positive effects on cognitive function ([@bib59]), indicating that treatment with carnitine may provide useful information on energy metabolism in cirrhosis and HCC.

Increased urinary and plasma carnitine and acylcarnitine levels have also been described in kidney diseases ([@bib17]; [@bib36]) and in patients treated with certain chemotherapeutic drugs, such as cisplatin ([@bib27]; [@bib40]).

Energy, nucleotide, and amino acid metabolism
---------------------------------------------

Other energy metabolism-related compounds found to be discriminatory between HCC and healthy cohorts include 2-oxoglutarate, succinate, and glycerol ([Table 7](#tbl7){ref-type="table"}). The elevation of 2-oxoglutarate, a key component of the TCA cycle, may be a consequence from a decreased mitochondrial respiration, that is, the Warburg effect. This hypothesis is strengthened by tissue metabolomics studies that report glycolytic phenotypes of HCC ([@bib44]). Contradictory urinary concentrations were reported for succinate, another TCA intermediate. A factor that may convolve the biological signal in urinary metabolite profiles is the extent of which a urinary metabolite concentration reflects the metabolite\'s blood concentration. Although the urinary metabolome is a subset of the total body metabolome, urinary metabolite concentrations depend on the renal excretion rate, which is metabolite specific and tightly regulated, depending on many factors such as blood pH. Evidence that supports this hypothesis is given in [@bib23] and [@bib14]. Furthermore, a number of amino acids were found to discriminate between HCC and healthy controls in serum and/or urine. An amino acid imbalance has been recognised previously in the serum of patients with CLD; specifically the decrease in branched chain amino acids (BCAAs: leucine, isoleucine, and valine) and the increase in aromatic amino acids (AAAs: phenylalanine, tryptophan, tyrosine, and histidine); in particular tyrosine ([@bib64]). This mainly has been supported by a metabonomic study, with an exception of phenylalanine, which was found increased in the sera of HCC patients, when compared to healthy controls. Decreased serum BCAAs may also be linked to elevated serum carnitine levels, since they are able to oxidise BCAAs ([@bib42]).

In addition, the urinary concentration of the purine nucleoside hypoxanthine has been found to be significantly higher in HCC when compared to healthy individuals. However, another study reports a decreased urine concentration, potentially due to the different HCC aetiologies of the cohorts. A tissue metabonomic study reported increased hypoxanthine concentrations in HCC tissue, compared to matched non-tumourous tissue of HCC patients ([@bib44]).

Other relevant metabolites, shown to be reduced in the urine of HCC patients, include creatinine and trimethylamine-*N*-oxide (TMAO). Urinary creatinine excretion is related to muscle mass ([@bib73]) and therefore may be a manifestation of cancer cachexia, instead of being specifically HCC related. Trimethylamine-*N*-oxide is generated in the liver from oxidation of the gut microbiota co-metabolite trimethylamine (TMA) by flavin monooxygenases. The production of TMA by the human gut microbiota may represent a link between HCC and interactions of host -- gut microbiota, which have previously been suggested to have the capacity to promote hepatocarcinogenesis ([@bib63]). In addition, increased TMAO levels may be partially responsible for decrease of serum bile acids, since TMAO is involved in cholesterol metabolism ([@bib48]).

Diagnostic performance of metabolite biomarker candidates
---------------------------------------------------------

From 22 studies reviewed, only 6 assessed the diagnostic performance of the biomarker candidates proposed ([@bib96]; [@bib19]; [@bib90]; [@bib102]; [@bib4]; [@bib44]). However, the performance of these metabonomic models to detect and differentiate HCC from healthy volunteers or cirrhosis patients is consistently better than the performance of AFP. The model with the best performance in discriminating HCC from cirrhosis cohort was constructed with full-serum LC-MS data (without variable selection), yielding 100% sensitivity and specificity (ROC=100% [@bib90]). A heavily reduced model, constructed with only canavaninosuccinate and AFP, achieved a sensitivity and specificity of 96.4 and 100%, respectively ([@bib90]). Another high-performance model for the discrimination between HCC and cirrhosis patients was obtained with acetylcarnitine C3 (propionylcarnitine) and betaine, yielding in an AUC of 0.98 ([@bib44]). A comparably high ROC value was obtained for a four-compound PLS-DA model for the discrimination between HCV infected cirrhosis patients with and without HCC, including methionine, 5-hydroxymethyl-2′-deoxyuridine, N2,N2-dimethylguanosine and uric acid ([@bib4]). The best model performance for the discrimination between HCC and healthy controls was based on serum levels of 1-methyladenosine combined with AFP, yielding in an AUC of 0.95 ([@bib19]). Very similar, in terms of performance, but without AFP was a model that included endocannabinoids anandamide and palmitylethanolamide yielding in an AUC of 0.94 ([@bib102]). The same model was used to discriminate between HCC and cirrhotics with an AUC of 0.88. A different model that included 13 serum components had an overall accuracy of 75% in discriminating HCC from healthy controls ([@bib96]). Only one urinary study evaluated the performance of an established PCA model for discriminating between HCC patients and healthy controls. Their model included 18 urinary compounds plus serum AFP and performed much better than AFP, with an AUC of 0.928 ([@bib93]). Taken together, these models seem to suggest that a robust diagnostic of HCC could be produced with a reduced panel of biomarkers rather than using the whole spectroscopic dataset. However, given that the panels of biomarker thus far reported in the literature have not been assessed in independent validation cohorts, there is now a pressing requirement for driving a full validation study for a selected biomarker panel.

HCC markers proposed by MS-based proteomics
-------------------------------------------

### State of the science

The PubMed search conducted using the search term stated in the Methods section resulted in the selection of 171 references. These were initially screened by methodology and all publications not utilising MS as a primary discovery approach were filtered out. The remaining references were read for adherence to the specified inclusion criteria leading to the exclusion of a further 31, leaving 29 to be used in this paper. Early studies applying MS techniques to clinical proteomics biomarker research exerted a greater focus on the utilisation of SELDI/MALDI ionisation platforms, occasionally coupled with weak/strong ion-exchange chromatography techniques for the identification of protein marker candidates. The MS analysis was typically applied in concert with two-dimensional electrophoresis methods where proteins separated according to their isoelectric points and molecular weights were observed on a global scale. Notable points of differentiation in spot patterns correlating with disease groupings would be excised for identification following in-gel digestion. Alternative approaches to marker discovery, which have since become more popular include untargeted analyses using tandem MS fragmentation methods to break up chromatographically separated proteins expressed in clinical samples followed by database-driven identification ([@bib72]). Both these approaches are applicable to pre-fractionated or un-fractionated samples as well as those which have undergone pre-enrichment steps for particular post-translational modifications (PTMs) of interest; a major form of this being glycosylation changes. This general shift from the coupling of gel-based classical proteomic approaches with MS to standalone chromatography-MS platforms has enabled researchers a greater detail in the analysis of the human proteome as well as increased flexibility and unmatched depth in finding biomarker targets.

Protein families
----------------

Proteomic exploration using MS is widely focussed on serum and plasma, which form the key body fluids with the greatest dynamic range of protein expression. This review of protein markers for HCC determined by MS in various populations identifies candidates from a wide range of protein families. Acute-phase and transport proteins, enzymes as well as proteins involved in various complementary and lipid metabolic pathways form some of the most commonly reported classes of biomarker candidates. Alongside these, a smaller number of proteins involved in numerous functions ranging from apoptosis, ion transport, host immunity, iron homoeostasis, protection from toxins and oxidative stress, cell adhesion, differentiation, regeneration, and death are reflected in the list of reported markers ([Table 8](#tbl8){ref-type="table"}). As the most frequently proposed protein subtype for biomarker candidates, the suggestion of acute-phase proteins as biomarker candidates is often eyed with scepticism as they are seen to lack specificity for particular disease processes. These proteins, however, constitute a well validated subset of proposed markers suggested from experiments run on numerous MS platforms in the context of HCC and CLDs. A1AT and alpha-1-antichymotrypsin (AACT) are major acute-phase proteins, which serve as protease inhibitors protecting tissues from the enzymatic action of inflammatory cells. Five independent publications identified these proteins as elevated in HCC patients; with a highest reported fold change of 5.3. Another large subset of proteins often reported following MS interrogation of HCC samples are apolipoproteins. These are proteins that bind lipids and cholesterols in the blood and lymphatic systems. Several isoforms, namely Apo A1, Apo J, Apo L1, and Apo B-100 have been consistently reported as downregulated in HCC. In particular, Apo J in its association with HCC has been implicated as a possible indicator of the metastatic potential of primary tumours ([@bib51]). In overall performance reports, some of the most consistently highlighted proteins include those with functional properties such as ion transport and scavenging, in particular -- iron homoeostasis. Haptoglobin and haemopexin are key players in the maintenance of haemoglobin and free haem in the blood. Haptoglobin binds free haemoglobin with high affinity and thus protects cells from its oxidative effects. Haemopexin on the other hand binds free haem released in the turnover of erythrocytes and preserves the body\'s iron stores. Like most of the proteins with unique expression trends concordant with liver disease, the specific mechanisms linking these proteins to CLD are not understood. However, amalgamated reports demonstrate that haptoglobins are largely increased in blood from HCC patients. Haemopexin in its whole and fucosylated forms follow the same trend with a suggestion in one report of a decrease in LC ([@bib34]).

Challenging discrepancies
-------------------------

This review identifies 31 individual proteins as showing differential signatures associated with a stage of liver disease. Each of these have undergone at least one level of validation whether in the context of the same publication or in an independent report. Overall, the direction of the alterations in protein expression are uniform, there however are some specific proteins, namely alpha-1-acid glycoprotein, afamin, complement component 3, and haptoglobin-related protein that demonstrate discrepancies in behaviour in selected case--control groupings. Alpha-1-acid glycoprotein, for example, is reported to be downregulated in HCC\'s in comparison to cirrhotics by one group ([@bib53]) and upregulated in HCC\'s *vs* LC\'s by another ([@bib46]). Complement component 3 shows a similar discrepancy in two studies ([@bib83]; [@bib2]). In each of these cases, key differences related to HCC assessment, sample pretreatment and MS platform used are likely contributors to the lack of consistency observed. Numerous publications included in this review and directly implicated in these discrepant examples have little to no clinical information on how LC or HCC cases were diagnosed ([@bib45]; [@bib2]), not to mention an almost uniform lack of staging data. For proteomic analyses in particular, different approaches exist to sample pretreatment, with options to deplete key abundant proteins, enrich for, or exclude ([@bib53]) particular PTMs. With albumin constituting ∼60% of the total protein content of blood ([@bib82]) and forming the backbone of many protein--protein interactions and complexes, its depletion could contribute to the loss of important endogenous signatures. Varying depletion protocol efficiencies may also impact directly on the accuracy of downstream quantitation. Additional separation by isoelectric or electrophoretic analysis according to molecular weight or isoelectric point whether 'in\' or 'off-gel\' can be applied to neat or pre-treated samples meaning that the final matrix injected into the MS instrument may already be severely biased towards identification of selected protein subtypes or sizes. This phenomenon along with varying MS platforms and ionisation methods will all contribute to the differences observed in shortlisted marker profiles at final analyses. Thus, the quantitative data assembled, though important cannot always be taken as conclusively reflective of endogenous expression. This can only be adequately assessed by targeted measurement of whole proteins using highly specific antibody-based methods or absolute quantitation by S/MRM MS analysis of unique peptide sequences in well-characterised sample cohorts.

Glycosylation and HCC
---------------------

An area of particular focus in terms of identifying unique exploitable changes for differential CLD diagnosis are those which occur in the glycosylation of many proteins during liver disease progression ([@bib13]). Glycosylation is essential to the tertiary and quaternary structures of many proteins bearing direct impact on their solubility and transport. The carbohydrate moieties bound to these modified proteins can be directly impacted by changes in host immunity and carcinogenesis. The surface of hepatocytes contain various receptors that bind proteins via their carbohydrate groups; when changes to the liver surface occur as a result of fibrosis, cirrhosis, or HCC, alterations in receptor distribution can lead to the accumulation of certain glycoproteins in the blood, which can be picked up by methods such as MS. As asparagine-linked (N-linked) glycosylation is the predominant form found in human sera, much research has been focussed on this particular subclass of glycoproteins. Investigations looking at the glycosylation patterns of key serum proteins associated with HCC and LC reports evidence of hyperfucosylation for 19 glycoproteins ([@bib26]) in the context of liver disease. Mass spectrometric assays conducted on lectin-enriched samples are seen to represent a sizable fraction of the protein markers identified in this review. Fucosylated haemopexin stands out as one of the highest performing candidate markers for HCC diagnosis with a reported AUC of 0.95 ([@bib25]). Numerous additional publications using lectin enrichment steps prior to MS analysis have identified various glycosylated proteins such as alpha-1-acid glycoprotein 1 (A1AG1), AACT, Apo L1, Apo J ([@bib1], [@bib2]), and several complement proteins as differentially expressed in HCC *vs* other disease stages. The multiply reported decline in the blood levels of various isoforms of the apolipoproteins involved in lipid and cholesterol metabolism have also been demonstrated to hold significant association with HCC.

Critical assessment and performance comparisons
-----------------------------------------------

In the presentation of candidates as potential biomarkers for HCC or any other condition; there has to be a widely applicable tool of measurement offering universal assessment of the potential usefulness and validity of a marker. Area under the curve reports with its achievable sensitivity and specificity at a chosen cut-off and fold change statistics form the most widely employed tools, and have become the benchmarks used for comparative assessment of candidates. Few studies report both AUC and fold change statistics as is seen in the comprehensive tables presented ([Tables 2](#tbl2){ref-type="table"} and [8](#tbl8){ref-type="table"}). As AFP is the only established non-invasive tool used for HCC diagnosis -- all biomarker studies are in effect in competition with its performance. One major gap, which exists in making comparative assessments with AFP within and across studies is that oftentimes the test forms an intrinsic part of the initial diagnostic profile used to classify subjects into the various clinical groups under evaluation. Without direct comparison of AFP and the gold standard in HCC diagnosis of liver biopsy within the *same* subject populations, no true evaluation of AFP performance can be accepted as an accurate reference point. In the absence of this, most publications are either mute on this point or address it by basing their performance evaluations on reported estimates for AFP performance often ranging between 0.6 and 0.7 with some dipping lower ([@bib38]).

Discussion and conclusion
=========================

This review serves as a focus for summarizing and highlighting metabonomic and proteomic literature on biomarkers for HCC in the urine and blood. A multitude of biomarker candidates have been proposed by comparative ^1^H NMR or MS analysis of urine and/or blood from HCC patients and various CLD groups. A review of these studies has shown that noteworthy changes occur at both the metabolite and protein levels, which correlate with disease aetiology and/or progression. Of significant note however are the multitudes of candidates, which do not appear to be reproducible but nevertheless weigh heavily on literature reports. These are vast in number and were filtered from this review, as they detracted from its stated aims. In order to move forward and accelerate the conversion of biomarker candidates into routine and robust tests to be used in clinics and the field, particularly in the developing world, this area of research must be held to a minimum standard of uniformity ([Table 9](#tbl9){ref-type="table"}) and from this facilitate a momentum shift from discovery to validation-based experiments. A noteworthy example is a recently conducted imaging MS study, which validated an altered phospholipid composition in HCC tumour tissues by transcriptomic analyses, thereby identifying LPCAT1 as a potential target molecule to inhibit HCC progression. A key limitation identified from the amalgamation of these reports, which is of particular significance in investigations targeting metabolites is the limited availability of descriptive statistics such as ROC analyses and fold change ratios offering quantitative measures of assessing the performance of a putative marker. Also missing in many studies are any efforts at validating the proposed biomarkers in distinct population sets. In both the proteomic and metabonomic papers reviewed, \<15% of publications included any attempts at independent validation of results. Without a consistent ability to reproduce primary discovery results in diverse populations, biomarkers will not accelerate on the pipeline towards serious consideration.

It is recognised that routine liver biopsy assessment of suspected HCCs is not readily available in many populations where the condition is endemic. The relevance of biopsy sample retrieval and definitive tumour staging however, cannot be overstated. For any new HCC diagnostic test to have a direct impact on reducing mortality from end-stage liver disease, it must be able to discern those at highest risk of progression to HCC from a background of LC or fibrosis as well as reflect early changes in the liver related to tumourigenesis. Most of the markers included in this review have been proposed from heterogeneous case groups where considerations such as background health of liver, tumour stage, and severity of cirrhosis or fibrosis have not been assessed or are not reported. Thus, when these candidates are proposed for validation studies, accurate case profiles must be presented that clearly stratify HCC stages in order to home in on how candidates perform in the diagnostic groups most difficult to distinguish. Best practice would warrant the clear and comprehensive distinction of these at the discovery stage but this is yet to be reflected in current practice. Some metabolites are correlated with the degree of cirrhosis or the hepatic compensation status of patients. For example, the metabolic profile of patients with small HCC tumours on a background of severe cirrhosis differs significantly from late HCC with minor background cirrhosis ([@bib69]). Group heterogeneity can thus bias results and impact directly on the range of proteins, metabolites, or pathways detected as significantly different. Such comprehensive descriptions and assessments are largely absent from current HCC biomarker literature and must be incorporated and prioritised in order to identify biomarker signatures of the highest impact.

Although the majority of studies presented provide detailed demographic data for participants, there was an observed lack of consistency in which clinical indices were reported in published works. Reports on liver biopsy rates and AFP levels are arguably of primary relevance to any HCC biomarker studies yet figures for these were present only in a fraction of papers. For AFP in particular, the cut-off taken as indicative of HCC, where reported, was still highly variable, ranging from 20 to 500 ng ml^−1^ depending on the specific study population or chosen guidelines. Alongside this, details on overall liver health, liver compensation status, clinical chemistry tests (e.g., liver enzymes and bilirubin), and the treatment status of participants were at best inconsistently reported. The absence or lack of consideration of these key clinical parameters will undoubtedly have significant implications on participant selection and classification as well as the interpretation of disease-specific signatures. Thus, a key recommendation to be made following this review is the need for some degree of uniformity in the rationale and level of detail forming the basis of case and control selection. Providing detailed case definitions would reduce or at least allow for the contextualisation of marked variations, which exist in the selection of cohorts. This could perhaps contribute to a wider overlap in identified proteins and metabolites associated with CLDs across different investigative platforms and thus offer greater consensus on which targets to validate.

In order to move some of the many suggested HCC biomarker targets forward and accelerate their conversion into routine and robust tests usable in clinics and the field, particularly in the developing world, the momentum of research must now shift from discovery to validation-based experiments -- focused both on expression level and mechanistic changes between clinically distinct groups. The populations involved in these studies must be well characterised to dissect biomarkers that are specific for (early) HCC and if these are still valid, in the presence of cirrhosis or other comorbidities. Below, we summarise key points that can significantly bias the results of a biomarker study on HCC. At the same time, we give recommendations, which with careful consideration could raise the likelihood of successful conversion of proposed biomarkers in the field of HCC research.

Although the consideration of these points and recommendations will not lead to uniform impact for all researchers in this field due to the diversity of challenges faced, it is however important that they are recognised as highly relevant and begin to be discussed on a larger scale.

![The search terms 'Proteomics\' or 'Metabonomics\' and 'Hepatocellular Carcinoma\' and 'Biomarker\' were entered into the search engine PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>). For the identification of metabonomic publications, an additional Google Scholar search was conducted for the time range 2003--2013 (<http://scholar.google.co.uk/>).](bjc201538f1){#fig1}

###### Number of metabonomic publications broken down to platform and specimen type

  **Biofluid**    ^**1**^**H NMR**  **MS**                               **Total**
  -------------- ------------------ ----------------------------------- -----------
  Urine                  2          3 (1[a](#t1-fn2){ref-type="fn"})         5
  Serum/plasma           3          13 (4[a](#t1-fn2){ref-type="fn"})       16
  Both                  ---         1                                        1
  Total                  5          17                                      22

Abbreviations: ^1^H NMR=proton nuclear magnetic resonance; MS=mass spectrometry.

Number of studies that included a validation cohort.

###### Summary of metabonomic studies that were reviewed

                                                                                                                                                                    **HCC group**                                      
  ----------- -------------- ------------------------------------------ ---------------------------------- ----- -------------------------------- ---------------- ---------------- ---------------------------------- ----------------------------
  [@bib4]         Serum                  HPLC--MS/MS (MRM)                       HCC: 30 CIR: 22            No                 HCV                    3.3 : 1            Yes                 Mainly Caucasian                       No
  [@bib19]        Serum                     UPLC--MS/MS                          HCC: 41 HCON: 38           No                 HBV                     2 : 1        No information               Chinese                            No
  [@bib22]        Serum                   UFLC--IT--TOF/MS               HCC: 30 CIR: 30 CHB: 30 HCON: 30   No                 HBV                 No information   No information               Chinese                            No
  [@bib21]        Serum                 UHPLC--TQ--MS (MRM)                      HCC: 29 HCON: 30           No            No information           No information   No information            No information                        No
  [@bib23]     Serum, urine         GC--TOF--MS, UPLC--qTOF--MS           HCC: 82 Benign LD: 24 HCON: 71    Yes             Mainly HBV                 2 : 1         Majority yes                Chinese                           TMN
  [@bib20]        Urine           RPLC--qTOF--MS, HILIC--qTOF--MS                HCC: 21 HCON: 24           Yes           No information             Partially      No information               Chinese                            No
  [@bib37]        Serum                       ^1^H NMR                       HCC: 39 CIR: 36 HCON: 63       No     HCC: HCV CIR: No information    No information   No information               Chinese                            No
  [@bib44]        Serum                   UHPLC--MS CE--MS                   HCC: 139 CIR: 78 CHB: 81       Yes      HCC: Mainly HBV CIR: HBV         5.3 : 1       No information            No information                        No
  [@bib68]        Serum                       ^1^H NMR                           HCC: 61 CIR: 93            Yes              Alcohol                   1 : 0             Yes         Caucasian or residence in France      Small HCC Large HCC
  [@bib75]        Plasma      UPLC--qTOF--MS UPLC--TQ--MS (MRM) GC--MS    HCC: 20 CIR: 7 AML: 22 HCON: 6    No    HCC: Mixed CIR: No information      5.6 : 1        Majority yes             No information               Barcelona criterion
  [@bib78]        Serum            UPLC--qTOF--MS, UPLC--MS (SRM)                HCC: 78 CIR: 184           No      HCC: Mainly HCV CIR: Mixed        5.5 : 1            Yes                 Mainly Caucasian           Yes (system not specified)
  [@bib80]        Urine                       ^1^H NMR                       HCC: 16 CIR: 14 HCON: 17       No              Mainly HCV                 15 : 1        Majority yes                Egyptian                         Okuda
  [@bib81]        Urine                       ^1^H NMR                       HCC: 18 CIR: 10 HCON: 14       No       HCC: Mainly HBV CIR: HBV          2 : 1        No information               Nigerian                         Okuda
  [@bib90]        Serum                       UPLC--MS                       HCC: 23 CIR: 28 HCON: 70       Yes                HBV                     12 : 1         Partially                  Chinese                           AJCC
  [@bib92]        Serum                       ^1^H NMR                           HCC: 40 CHC: 22            No                 HCV                    3.3 : 1       No information           Mainly Caucasian                       No
  [@bib93]        Urine                        GC--MS                            HCC: 20 HCON: 20           No            No information               1 : 0        No information               Chinese                            No
  [@bib95]        Serum           UPLC--qTOF--MS UPLC--MS/MS (SRM)               HCC: 40 CIR: 49            No       HCC: HCV CIR: Mainly HCV         3.4 : 1       No information               Egyptian                          TMN
  [@bib96]        Serum                        GC--MS                            HCC: 20 HCON: 20           No            No information               1 : 0        No information               Chinese                            No
  [@bib99]        Serum           RPLP--qTOF--MS, HILIC--qTOF--MS            HCC: 24 CIR: 25 HCON: 25       No     HCC: No information CIR: HBV    No information     Partially                  Chinese                            No
  [@bib100]       Urine                   UPLC--qTOF--HDMS                       HCC: 25 HCON: 12           No            No information               1 : 1        No information               Chinese                            No
  [@bib102]       Serum                 UPLC--qTOF--MS (MRM)                 HCC: 69 CIR: 28 HCON: 31       No             HBV and HCV                4.3 : 1       No information               Chinese                            No
  [@bib103]       Serum                    RPLC--qTOF--MS                HCC: 30 CIR: 30 CHB: 30 HCON: 30   No            No information              2.3 : 1            Yes                     Chinese                            No

Abbreviations: AJCC=American Joint Committee on Cancer; AML=acute myeloid leukaemia; CE=capillary electrophoresis; CHB=chronic hepatitis B; CHC=Carcinome HepatoCellulaire; CIR=cirrhosis cohort; CLD=chronic liver disease; GC=gas chromatography; HBV=hepatitis B virus; HCC=hepatocellular carcinoma; HCON=healthy control cohort; HCV=hepatitis C virus; HDMS=high-definition mass spectrometry; HILIC=hydrophobic interaction chromatography; IT=ion trap; MRM=multiple reaction monitoring; MS=mass spectrometry; NMR=nuclear magnetic resonance; qTOF=quadrupole time of flight; RPLC=reversed phase liquid chromatography; SRM=single reaction monitoring; TOF=time of flight; TQ=triple quadrupole; UFLC=ultra-fast liquid chromatography; UHPLC=ultra-high-performance liquid chromatography; UPLC=ultra-performance liquid chromatography.

###### Bile acid compounds discriminatory between HCC and comparison group

                                                          **HCC: Healthy**                     **HCC: Cirrhosis**                               
  --------- ------- --------------------- ------------------------------------------------ --------------------------- ------------------------ ---
  GCA        00138        Bile acid         ↑ ([@bib99]; [@bib23]; [@bib102], [@bib103])     ↑ ([@bib23]; [@bib100])    ↓ ([@bib78]; [@bib95])    
  GCDCA      00637        Bile acid        ↑ ([@bib99]; [@bib23]; [@bib90]; [@bib103])^†^                               ↓ ([@bib90]; [@bib95])    
  GDCA       00631        Bile acid                   ↑ ([@bib75]; [@bib102])                                           ↓ ([@bib78]; [@bib95])    
  TCA        00036        Bile acid                  ↑ ([@bib99]; [@bib23])^†^                                                                    
  TCDCA      00951        Bile acid                                                                                     ↓ ([@bib78]; [@bib95])    
  Glycine    00123   Bile acid conjugate                                                    ↓ ([@bib80]) ↑ ([@bib93])                             
  Taurine    00251   Bile acid conjugate             ↓ ([@bib99]) ↑ ([@bib23])                                                                    

Abbreviations: GCA=glycocholic acid; GCDCA=glycochenodeoxycholic acid; GDCA=glycodeoxycholic acid; HCC=hepatocellular carcinoma; HCV=hepatitis C virus; HMDB=The Human Metabolome Database; TCA=taurocholic acid; TCDCA=taurochenodeoxycholic acid.

↓ indicates decrease in HCC; ↑ indicates increase in HCC; † indicates control group of the study ([@bib99]) comprised chronic HCV carriers.

###### LPCs reported to be discriminatory between HCC and comparison groups

                                                                                 **HCC: Healthy**                      **HCC: Cirrhosis**                                                   
  ------------- ------------------- ------------------------- ------------------------------------------------------- -------------------- ------------------------------------------------ ---
  LPC C14 : 0          10379         Phospholipid catabolism             ↓ ([@bib75]; [@bib103]; [@bib21])                                                                                    
  LPC C16 : 0          10382         Phospholipid catabolism   ↓ ([@bib75]; [@bib90]; [@bib102]; [@bib21], [@bib22])                        ↓ ([@bib75]; [@bib102]) ↑ ([@bib78]; [@bib90])    
  LPC C18 : 0          10384         Phospholipid catabolism       ↓ ([@bib99]; [@bib75]; [@bib90]; [@bib102]; )                                        ↑ ([@bib78]; [@bib90])                
  LPC C18 : 1    02815/10385/10408   Phospholipid catabolism             ↓ ([@bib75]; [@bib102]; [@bib21])                                                                                    
  LPC C18 : 2          10386         Phospholipid catabolism   ↓ ([@bib99]; [@bib102]; [@bib4]; [@bib21], [@bib22])                                                                           
  LPC C18 : 3          10386         Phospholipid catabolism                  ↓ ([@bib99]; [@bib75])                                                                                          
  LPC C20 : 3       10393/10394      Phospholipid catabolism                  ↓ ([@bib75]; [@bib103])                                                                                         
  LPC C20 : 4       10395/10396      Phospholipid catabolism                  ↓ ([@bib75]; [@bib102])                                                                                         
  LPC C20 : 5          10397         Phospholipid catabolism                  ↓ ([@bib75]; [@bib103])                                                                                         

Abbreviations: HCC=hepatocellular carcinoma; HMDB=The Human Metabolome Database; LPCs=lysophosphatidylcholines.

↓ indicates decrease in HCC; ↑ indicates increase in HCC.

###### Discriminative FFAs between HCC and comparison groups

                                                                                            **HCC: Healthy**               **HCC: Cirrhosis**                           
  -------------------------------- ------- ------------------------------------ ----------------------------------------- -------------------- ------------------------ ---
  FFA C24 : 1 (nervonic acid)       02368   Lipid metabolism/energy metabolism           ↓ ([@bib23]; [@bib75])                                                           
  Oleamide                          02117   Lipid metabolism/energy metabolism          ↓ ([@bib23]) ↑ ([@bib90])                               ↓ ([@bib90]; [@bib95])    
  FFA C16 : 0 (palmitic acid)       00220   Lipid metabolism/energy metabolism   ↓ ([@bib23]) ↑ ([@bib103]) • ([@bib96])                                                  
  FFA C18 : 0 (stearic acid)        00827   Lipid metabolism/energy metabolism   ↓ ([@bib23]) ↑ ([@bib103]) • ([@bib96])                                                  
  FFA C20 : 4 (arachidonic acid)    01043   Lipid metabolism/energy metabolism    ↓ ([@bib23]) ↑ ([@bib102], [@bib103])                                                   

Abbreviations: FFAs=free fatty acids; HCC=hepatocellular carcinoma; HMDB=The Human Metabolome Database.

↓ indicates decrease in HCC; ↑ indicates increase in HCC; • indicates not reported whether decreased or increased.

###### Discriminative carnitines between HCC and comparison groups

                                                                      **HCC: Healthy**                         **HCC: Cirrhosis**                                      
  ----------------------- ------- ------------------- ------------------------------------------------ ---------------------------------- ---------------------------- ------------------------
  Carnitine                00062   Energy metabolism   ↑ ([@bib99]; [@bib23]) ↓ ([@bib103]; [@bib44])   ↑ ([@bib20]; [@bib81], [@bib80])                                ↑ ([@bib81], [@bib80])
  Acetylcarnitine          00201   Energy metabolism             ↑ ([@bib99]) ↓ ([@bib103])                                                                                        
  Acylcarnitine C3 : 0     00824   Energy metabolism              ↓ ([@bib103]; [@bib44])                                                                                          
  Acylcarnitine C8 : 0     00791   Energy metabolism              ↓ ([@bib103]; [@bib21])                                                                                          
  Acylcarnitine C8 : 1     00791   Energy metabolism              ↓ ([@bib103]; [@bib21])                                                                                          
  Acylcarnitine C10 : 0    00651   Energy metabolism              ↓ ([@bib103]; [@bib21])                                                                                          
  Acylcarnitine C10 : 1    13205   Energy metabolism              ↓ ([@bib103]; [@bib21])                                                                                          
  Acylcarnitine C18 : 1    13338   Energy metabolism         ↑ ([@bib102], [@bib103]; [@bib21])                                            ↓ ([@bib95]) ↑ ([@bib102])              
  Acylcarnitine C18 : 2    13212   Energy metabolism         ↑ ([@bib102], [@bib103]; [@bib21])                                             ↓ ([@bib95]; [@bib102])                

Abbreviation: HBV=hepatitis B virus; HCC=hepatocellular carcinoma; HMDB=The Human Metabolome Database.

↓ indicates decrease in HCC; ↑ indicates increase in HCC; † indicates control group of the study ([@bib44]) comprised chronic HBV carriers.

###### Additional metabolites associated with TCA cycle, and protein and nucleotide metabolism

                                                                                               **HCC: Healthy**                               **HCC: Cirrhosis**                                              
  -------------------------- ------- ------------------------------------ ---------------------------------------------------------- ------------------------------------- ---------------------------------- ------------------------
  Isoleucine                  00687          AA/protein synthesis                         ↓ ([@bib21]) • ([@bib96])                                                                                                       
  Leucine                     00687          AA/protein synthesis                           ↓ ([@bib23], [@bib21])                                                                                                        
  Methionine                  00696          AA/protein synthesis                  ↓ ([@bib23]; [@bib44]) ^†^) ↑ ([@bib21])                                                                                               
  Phenylalanine               00159          AA/protein synthesis          ↓ ([@bib23]) ↑ ([@bib37]; [@bib90]; [@bib102]; [@bib21])                                         ↓ ([@bib90]; [@bib102]; [@bib4])              
  Threonine                   00167          AA/protein synthesis                                                                           ↑ ([@bib93]; [@bib23])                                                        
  Tryptophan                  00929          AA/protein synthesis                ↓ ([@bib23], [@bib21]; [@bib102], [@bib103])                                                                                             
  Tyrosine                    00158          AA/protein synthesis                    ↑ ([@bib37]; [@bib21]) ↓ ([@bib23])                    ↑ ([@bib93]; [@bib23])                                                        
  Valine                      00883          AA/protein synthesis                  ↓ ([@bib37]; [@bib21]) ↑ ([@bib92]) ^†^                                                                                                
  Creatinine                  00562     Alanine and proline metabolism                    ↓ ([@bib23]; [@bib92]) ^†^                   ↓ ([@bib20]; [@bib81], [@bib80])                                        ↑ ([@bib81], [@bib80])
  Choline                     00097            Lipid metabolism                         ↑ ([@bib92]) ^†^) ↓ ([@bib37])                                                                                                    
  Glycerol                    00131   Lipid metabolism/energy metabolism            ↓ ([@bib23]) ↑ ([@bib37]) • ([@bib96])                                                                                                
  Trimethylamine *N*-oxide    00925        Microbial co-metabolite                                                                          ↓ ([@bib80]; [@bib23])                                                        
  Creatine                    00064                 Other                                                                             ↓ ([@bib23]) ↑ ([@bib81], [@bib80])                                                 
  Hypoxanthine                00157           Purine nucleoside                                                                       ↓ ([@bib93]) ↑ ([@bib20], [@bib23])                                                 
  2-Oxoglutarate              00208               TCA cycle                                 ↑ ([@bib37], [@bib23])                                                                                                        
  Succinate                   00254               TCA cycle                                                                                 ↓ ([@bib93]; [@bib23])                                                        

Abbreviation: AA=amino acid; HBV=hepatitis B virus; HCC=hepatocellular carcinoma; HCV=hepatitis C virus; HMDB=The Human Metabolome Database; TCA=tricarboxylic acid.

↓ indicates decrease in HCC; ↑ indicates increase in HCC; † indicates control group of the study ([@bib44]; [@bib92]) comprised chronic HCV or HBV carriers, respectively.

###### Summary of proteomic studies that were reviewed

  **Protein (key role)**                            **UniProt ID**   **Biofluid**   **Relation to HCC (↑, ↓)**              **HCC LB rate**                                                            **Cohort sizes**                                                **Aetiology**   **AUROC**        **Fold change**                          **Platform**                        **Reference**
  ------------------------------------------------ ---------------- -------------- ---------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------- ----------- -------------------------- --------------------------------------------------- --------------------
  AGP1 (AP: Transport)                                  P02763          Plasma              ↑ HCC:CON                        No information                                                 \*10 HCC; 30 controls (healthy/LC/HBV)                                          HBV        0.73                  1.6\*                         Lectin MRM--UPLC--ESI--MS               [@bib1], [@bib2]\*
                                                                        Plasma               ↓ HCC:LC                        No information                                                Disc: 10 HCC/2 HCON Val: 18 HCC, 10 HCON                                    No information  0.65                   ---                        nUPLC--ESI--QTOF--MS and QQQ                   [@bib53]
                                                                        Serum                ↑ HCC:LC                           100% ALL                                                      Disc: 9 HCC/9 LC Val: 52 HCC/40 LC                                            HBV        ---                   1.8^†^                          ICAT--LC--ESI--MS/MS                       [@bib46]
  A1AT (AP: Protease inhibitor)                         P01009          Plasma              ↑ HCC:CON                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   0.84                   ---                             QTOF--LC--MS, ELISA                       [@bib34]
                                                                        Plasma              ↑ HCC:CON                        No information                                                 \*10 HCC; 30 controls (healthy/LC/HBV)                                          HBV        0.92                2.4^\*\*^                       Lectin MRM--UPLC--ESI--MS               [@bib1], [@bib2]\*
                                                                        Serum               ↑ HCC:CON                        No information                                       Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON                                HBV        ---                    ---                           MALDI--TOF--MS/MS, 2DE                      [@bib31]
  A2M (Protease inhibitor)                              P01023          Plasma              ↑ HCC:CON                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   ---                   1.13\*                          QTOF--nUPLC--ESI--MS                       [@bib34]
                                                                        Serum                ↓ HCC:LC                         100% of HCCs                                                    Disc: 9 HCC/9 LC Val: 52 HCC/40 LC                                            HBV        ---                  0.26^†^                          ICAT--LC--ESI--MS/MS                       [@bib46]
  AACT (AP: Protease inhibitor)                         P01011          Plasma              ↑ HCC:CON                        No information                                                 \*10 HCC; 30 controls (healthy/LC/HBV)                                          HBV        0.93                3.7^\*\*^                       Lectin MRM--UPLC--ESI--MS               [@bib1], [@bib2]\*
                                                                        Plasma              ↑ HCC:CON                        No information                                                             6 HCC, 3 HCON                                                  No information  ---                   5.3\*                           2D LC--MALDI--TOF/TOF                      [@bib45]
  AFM (Vitamin transport)                               P43652          Plasma              ↑ HCC:CON                        No information                                                             6 HCC, 3 HCON                                                  No information  ---                  33.1^†^                          2D LC--MALDI--TOF/TOF                      [@bib45]
                                                                        Plasma              ↓ HCC:CON                        No information                                                            28 HCC, 10 HCON                                                 No information  0.72                   ---                        nUPLC--ESI--QTOF--MS and QQQ                   [@bib53]
  **Apolipoproteins**                                                                                                                                                                                                                                                                                                                                                             
  Apo A1 (Cholesterol metabolism)                       P02647          Plasma              ↓ HCC:CON                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   0.83                   ---                            QTOF--nUPLC--ESI--MS                       [@bib34]
                                                                        Serum               ↓ HCC:CON                         100% of HCCs                                                             20 HCC, 20 HCON                                                 No information  ---                  −3.59\*                       2DE-coupled MALDI--TOF--MS                    [@bib86]
                                                                        Serum               ↓ HCC:CON                         100% of HCCs                                                          8 HCC, 21 HBV, 7 HCON                                                   HBV        ---                  −3.10^†^                      2DE-coupled MALDI--TOF--MS                    [@bib83]
  Apo B-100 (Cholesterol metabolism)                    P04114          Plasma              ↓ HCC:CON                        No information                                                             6 HCC, 3 HCON                                                  No information  ---                   −3.7\*                          2D LC--MALDI--TOF/TOF                      [@bib45]
  Apo L1 (Cholesterol metabolism)                       O14791          Plasma              ↓ HCC:CON                        No information                                                 \*10 HCC; 30 controls (healthy/LC/HBV)                                          HBV        0.68                 0.5^ns^                        Lectin MRM--UPLC--ESI--MS               [@bib1], [@bib2]\*
  B2M (Immunity)                                        P61769          Plasma              ↑ HCC:CON                        No information                                                      6 HCC, 16 LC/HBV/HCV, 8 HCON                                             HCV/HBV      ---                    ---                               SELDI--TOF--MS                          [@bib70]
                                                                        Serum              ↑HCC:pre-HCC                 Some Histo. % not stated          38 Pre-HCC; 35 samples upon clinical diagnosis of HCC; 18 samples post treatment (longitudinal collection)        HCV        ---                 1.82^\*\*^                           SELDI--TOF--MS                          [@bib91]
  C4B-*α* (Complement pathway)                          P04003          Plasma              ↑ HCC:CON                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   ---                  1.25^ns^                         QTOF--nUPLC--ESI--MS                       [@bib34]
                                                                                            ↑ HCC:CON                        No information                                                        \*10 HCC; 30 HCON/LC/HBV                                                 HBV        0.66                 1.3^ns^                        Lectin MRM--UPLC--ESI--MS               [@bib1], [@bib2]\*
  CC3 (Complement pathway)                              P01024          Plasma              ↑ HCC:CON                        No information                                                         10 HCC; 30 HCON/LC/HBV                                                  HBV        0.67                 2.0^ns^                        Lectin MRM--ESI--UPLC--MS                    [@bib2]
                                                                        Plasma               ↑ HCC:LC                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   0.70                   ---                         QTOF--nUPLC--ESI--MS, ELISA                   [@bib34]
                                                                        Serum               ↓ HCC:CON                         100% of HCCs                                                          8 HCC, 21 HBV, 7 HCON                                                   HBV        ---                −1.87^\*\*^                     2DE-coupled MALDI--TOF--MS                    [@bib83]
  CC3-*α*                                                               Serum              ↑HCC:CLD/CON                       No LBs done                                                          45 HCC, 42 CLD, 21 HCON                                                  HCV        0.70                   ---                               SELDI--TOF--MS                          [@bib47]
                                                                                           ↑HCC:CLD/CON                      No information                                                            28 HCC, 10 HCON                                                      HCV        ---          n/r but *P* of Δ 0.00001                  SELDI--TOF--MS, WB                        [@bib52]
  CERU (Cu/ion transport)                               P00450          Plasma              ↑ HCC:CON                        No information                                                        10 HCC; 30 HCON/LC/HBV)                                                  HBV        0.77                1.5^\*\*^                       Lectin MRM--UPLC--ESI--MS                    [@bib2]
                                                                        Plasma              ↑ HCC:CON                        No information                                                             6 HCC, 3 HCON                                                  No information  ---                   6.8^†^                          2D LC--MALDI--TOF/TOF                      [@bib45]
                                                                        Serum                HCC only                         100% of HCCs                                                              5 HCC, 5 HCON                                                     HCV/HBV      ---                    ---                            nanoHPLC--ESI--MS/MS                       [@bib97]
                                                                        Serum               ↑ HCC:CON                        No information                                       Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON                                HBV        ---                    ---                          2DE and MALDI--TOF--MS/MS                    [@bib31]
  CLU (apoptosis/complement pathway)                    P10909       Plasma/serum           ↓ HCC:CON                        No information                                                             No information                                                 No information  ---                    ---                                SID--MRM--MS                          [@bib101]
                                                                        Plasma              ↓ HCC:CON                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   ---                   0.59\*                          QTOF--nUPLC--ESI--MS                       [@bib34]
                                                                        Plasma              ↓ HCC:CON                        No information                                                         10 HCC; 30 HCON/LC/HBV                                                  HBV        0.70                 0.8^ns^                        Lectin MRM--UPLC--ESI--MS                [@bib1], [@bib2]
                                                                        Serum               ↑ HCC:CON                        No information                                       Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON                                HBV        ---                    ---                          2DE and MALDI--TOF--MS/MS                    [@bib31]
  ERBB3 (Signalling pathway)                            P21860          Serum              ↑HCC:LC/CON            Disc and Val 1--100% Val 2; Unclear            Disc: 10 total, HCC and non-HCC Val 1: 113 HCC, 47 LC, 64 HBV/HCV Val 2: 57 HCC, 35 HBV/HCV              HBV/HCV      0.93/0.71              ---                          MALDI--TOF--MS, WB, ELISA                    [@bib43]
  GFAP (cell differentiation/regeneration)              P14136          Serum               ↑ HCC:CON                          100% HCCs                                                   Disc: 20 HCC, 20 HCON Val: 5 HCC, 5 HCON                                    No information  ---                    ---                         2DE-coupled MALDI--TOF, WB                    [@bib94]
  hCE1 (response to toxins)                             P23141          Plasma              ↑ HCC:CON                        No information                                  24 HCC, 14 LC, 7 CH, 8 CCa, 15 stomach cancer, 16 pancreatic cancer                       No information  0.80                   ---                    2DE MALDI--TOF/TOF, nano-LC MS/MS, WB              [@bib67]
  HP (AP: Immunity and Fe homoeostasis)                 P00738          Serum               ↑ HCC:CON                         100% of HCCs                                                              5 HCC, 5 HCON                                                     HCV/HBV      ---                    ---                             2DE LC--ESI--MS/MS                        [@bib97]
                                                                        Serum               ↑ HCC:CLD                         100% of HCCs                                                              56 HCC, 40 CLD                                                 No information  0.73                2.57^\*\*^                                ELISA                              [@bib3]
                                                                        Serum               ↑ HCC:CON                        No information                                       Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON                                HBV        ---                    ---                          2DE and MALDI--TOF--MS/MS                    [@bib31]
                                                                        Serum               ↑ HCC:CON                         100% of HCCs                                                             20 HCC, 20 HCON                                                 No information  ---                 5.10^\*\*^                     2DE-coupled MALDI--TOF--MS                    [@bib86]
                                                                        Plasma               ↑ CON:LC                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   ---                   1.35\*                          QTOF--nUPLC--ESI--MS                       [@bib34]
  HPR (metabolic process)                               P00739          Serum               ↑ HCC:CON                         100% of HCCs                                                              5 HCC, 5 HCON                                                     HCV/HBV      ---                    ---                             2DE LC--ESI--MS/MS                        [@bib97]
                                                                        Plasma              ↓ HCC:CON                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   ---                   0.65\*                          QTOF--nUPLC--ESI--MS                       [@bib34]
  HPX (Fe homoeostasis)                                 P02790          Plasma              ↑ HCC:CON                        No information                                                         10 HCC; 30 HCON/LC/HBV                                                  HBV        0.61                 1.2^ns^                        Lectin MRM--UPLC--ESI--MS                    [@bib2]
                                                                        Plasma               ↑ CON:LC                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   0.81                   ---                            QTOF--nUPLC--ESI--MS                       [@bib34]
  Fu-HPX                                                                Plasma              ↑ HCC:CON                   Some Histo. % not stated                               72 HCC, 32 LC, 33 HBV, 133 HCV, 62 other liver diseases, 20 CON                            HCV/HBV      0.95                1.4^\*\*^                           Lectin LC--MS/MS                         [@bib25]
  HSP90 (stress response)                               P08238          Serum               ↑ HCC:CON                         100% of HCCs                                                             20 HCC, 20 HCON                                                 No information  ---                 7.04^\*\*^                        MALDI--TOF--MS, ELISA                      [@bib86]
  OPN (biomineralisation/cell adhesion)                 P10451          Plasma             ↑HCC:CLD/CON                        Val: None                                        Disc: 17 HCC, 18 LC Val: 131 HCC, 76 LC, 52 CHCV/HBV, 53 HCON                             HCV/HBV      0.76                   ---              LC--ESI--MS/MS with 2D nHPLC-coupled LTQ OrbiTrap        [@bib79]
                                                                        Plasma             ↑HCC:CON/LC                  Some Histo. % not stated                                                    30 HCC, 30 LC, 20 HCON                                                  HCV        0.92                 4.33^†^                                  ELISA                              [@bib28]
  PON-1 (antioxidant/hydrolase)                         P27169          Serum               ↑ HCC:CON                         100% of HCCs                                                              5 HCC, 5 HCON                                                     HCV/HBV      ---                    ---                             2DE LC--ESI--MS/MS                        [@bib97]
                                                                        Plasma              ↓ HCC:CON                     Disc 24.2% Val 4.8%                                 Disc: 120 HCC, 99 LC, 120 HCON Val: 21 HCC, 6 LC, 18 ASC, 10 HCON                        HBV/aflatoxin   ---                 0.63^\*\*^                        QTOF--nUPLC--ESI--MS                       [@bib34]
  Prx-II (antioxidant/oxidoreductase/peroxidase)        P32119          Plasma               ↑ LC:CON                        100% of cases                                                Disc: 27 HBV, 7 HCON Val: 68 HBV, 42 HCON                                         HBV        1.00                   ---                               MALDI--TOF--MS                          [@bib57]
                                                                        Tissue              ↑ HCC:CON                         100% of HCCs                                                  6 HCC, 6 non-malignant adjacent tissue                                          HBV        ---                   2.1^†^                       2DE-coupled MALDI--TOF--MS                    [@bib62]
  SAA (AP and innate response/cell adhesion)            P0DJI8          Serum               ↑ HCC:CON                        No information                                                        67 HCC, 53 CHBV, 44 HCON                                                 HBV        ---                   4.5^†^                   2DE MALDI--TOF--MS, SELDI--TOF--MS                [@bib39]
                                                                        Serum                HCC only                         100% of HCCs                                                              5 HCC, 5 HCON                                                     HCV/HBV      ---                    ---                              2DE LC ESI--MS/MS                        [@bib97]
  SGP-2 (cell death)                                    Q6LDQ3          Serum               ↑ HCC:CON                          100% HCCs                                                   Disc: 20 HCC, 20 HCON Val: 5 HCC, 5 HCON                                    No information  ---                    ---                           2DE MALDI--TOF--MS, WB                      [@bib94]
  TGM2 (apoptosis/transferase)                          P21980       Tissue/serum           ↑ HCC:CON                      ALL: 100% of HCCs                               Tissue disc: 61 HCC, 61 adjacent non-tumour tissue Val: 109 HCC, 42 HCON                       HBV/HCV      ---                    ---                            LTQ--FT--MS/MS, ELISA                      [@bib85]
  TTR (Transport)                                       P02766          Serum               ↓ HCC:CON                        No information                                       Disc: 20 HCC, 20 HBV, 20 HCON Val: 20 HCC, 20 HBV, 20 HCON                                HBV        ---                    ---                          2DE and MALDI--TOF--MS/MS                    [@bib31]
                                                                        Serum               ↓ HCC:CON                         100% of HCCs                                                              5 HCC, 5 HCON                                                     HCV/HBV      ---                    ---                             2DE LC--ESI--MS/MS                        [@bib97]
  VIM (host-virus interaction)                          P08670       Tissue/serum          ↑HCC:LC/CON           Disc: 100% of HCCs Val: No information                               Disc (tissue): 40 HCC, 36 CON Val: 88 HCC, 64 CON                                     HBV        0.69                 3.27^†^                        2DE MALDI--TOF/TOF, ELISA                    [@bib84]
  VIT (cell adhesion)                                   P04004          Serum                ↑ HCC:LC                         91% of HCCs                                                               44 HCC, 38 LC                                                  No information  0.85                   ---                               SELDI--TOF--MS                          [@bib74]
                                                                        Serum               ↓ HCC:CON                        No information                                                            10 HCC, 10 HCON                                                 No information  ---                    ---                                SID--MRM--MS                          [@bib101]
                                                                        Plasma              ↑ HCC:CON                        No information                                                         10 HCC; 30 HCON/LC/HBV                                                  HBV        0.54                 1.1^ns^                        Lectin MRM--UPLC--ESI--MS                    [@bib2]
                                                                        Plasma              ↓ HCC:CON                        No information                                                            28 HCC, 10 HCON                                                 No information  0.98                   ---                        nUPLC--ESI--QTOF--MS and QQQ                   [@bib53]

Abbreviations: 2D=two dimensional; 2DE=two-dimensional electrophoresis; ASC=asymptomatic carrier; AUROC=area under receiver operating characteristics; CCa=cholangiocarcinoma; CHBV/CHCV=chronic HBV or HCV; CLD=chronic liver disease; ELISA=enzyme-linked immunosorbent assay; ESI=electrospray ionisation; HBV=hepatitis B virus; HCC=hepatocellular carcinoma; HCON=healthy control; HCV=hepatitis C virus; Histo=histology; ICAT=isotope-coded affinity tag; LB=liver biopsy; LC=liquid chromatography; MALDI=matrix-assisted laser desorption/ionization; MRM=multiple reaction monitoring; MS=mass spectrometry; n/r=not recorded; nanoHPLC=nano high-performance liquid chromatography; nUPLC=nano ultra-performance liquid chromatography; QQQ=triple quadropole mass spectrometer; qTOF=quadrupole time of flight; WB=western blot; SELDI=surface-enhanced laser desorption/ionization; TOF=time-of-flight. \**P*\<0.05; \*\**P*\<0.01; ns, non-significant; †, no *P*-value reported.

###### Recommendations for future metabonomic and proteomic studies on HCC

  **Key point**                                            **Recommendation**
  -------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Use of published guidelines to inform case definitions   CLD diagnosis should be made using agreed international guidelines (e.g., EASL and AASLD). New guidelines must be developed/adapted for areas of HCC endemicity in the developing world
  Measure of total protein expression                      Use commercial assays (e.g., QuantiPro BCA) to quantify and normalise total protein expression in sampled blood
  Prandial state                                           8--12 h Pre-prandial
  Physical exercise                                        Should be avoided immediately prior to sample collection
  Overall liver function                                   Assessment of Child-Pugh score:  A: Hepatic compensated  B: Slightly decompensated liver state  C: Hepatic decompensated
  Tumour size and nodularity                               Tumour staging, for example, TMN classification
  Comorbidities                                            Clinical assessment of cirrhosis in the background of HCC Clinical assessment of renal impairment, for example, kidney function tests such as glomerular filtration rate (important for urinary analyses)
  Tumour size and nodularity                               Tumour staging, for example, TMN classification
  Validation of the diagnostic model                       Inclusion of external validation cohorts, for example, early HCCs, different HCC aetiologies, and tumour controls
  Performance assessment of the diagnostic model           AUROC statistic, enables direct comparison to other models and AFP

Abbreviations: AASLD=American Association for the Study of Liver Diseases; AFP=alpha-fetoprotein; AUROC=area under receiver operating characteristics; BCA=bicinchoninic acid; CLD=chronic liver disease; EASL=European Association for the Study of the Liver; HCC=hepatocellular carcinoma; TNM=tumour, nodes, and metastasis.
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